Search
Clinician Ordering Portal
Scientific Evidence
Individualized risk prediction in Barrett’s esophagus
Jul 2016
Barrett’s esophagus management decisions are often based on subjective diagnoses, so better information and techniques are needed to aid in BE patient care.
Publication: Medical Laboratory Observer
Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma
Jul 2016
Uveal melanoma (UM) can be divided into prognostically significant subgroups based on a prospectively validated and widely used 15-gene expression profile (GEP) test. Class 1 UMs have a low risk and class 2 UMs have a high risk for metastasis.
Publication: JAMA Ophthalmol.
Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes
Jul 2016
Frequent mutations have been described in the following 5 genes in uveal melanoma (UM): BAP1, EIF1AX, GNA11, GNAQ, and SF3B1. Understanding the prognostic significance of these mutations could facilitate their use in precision medicine.
Publication: JAMA Ophthalmol
Individualized risk prediction in Barrett’s esophagus
Jul 2016
Barrett’s esophagus management decisions are often based on subjective diagnoses, so better information and techniques are needed to aid in BE patient care.
Publication: Medical Laboratory Observer
Clinical performance and management outcomes with the DecisionDx-UM gene expression profile test in a prospective multicenter study
Jun 2016
Uveal melanoma management is challenging due to its metastatic propensity. DecisionDx-UM is a prospectively validated molecular test that interrogates primary tumor biology to provide objective information about metastatic potential that can be used in determining appropriate patient care. To evaluate the continued clinical validity and utility of DecisionDx-UM, beginning March 2010, 70 patients were enrolled in a prospective, multicenter, IRB-approved study to document patient management differences and clinical outcomes associated with low-risk Class 1 and high-risk Class 2 results indicated by DecisionDx-UM testing.
Publication: Journal of Oncology
A tissue systems pathology assay for high-risk Barrett’s esophagus
May 2016
Exploration of a tissue systems pathology approach to predict progression in patients with non-dysplastic Barrett's esophagus.
Publication: Cancer Epidemiology, Biomarkers & Prevention
A tissue systems pathology test detects a field effect associated with high-grade dysplasia and esophageal cancer in Barrett’s esophagus patients
May 2016
TissueCypher better predicts the presence of HGD and EAC in BE than pathologic variables and can improve histology to identify patients requiring therapy.
Publication: Poster presentation (Sa1257) at DDW 2016, San Diego
Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients
May 2016
Post-test management plans were changed in 53% of patients who had risk aligned management changes concordant with a Class 1 (low risk) or Class 2 result (high risk).
Publication: Current Medical Research and Opinion
A cost-effectiveness analysis of a test that predicts risk of malignant progression in Barrett’s esophagus
May 2016
TissueCypher is cost-saving after five years and improves patient outcomes due to improving the effectiveness of surveillance and treatment.
Publication: Podium presentation (CN4) at ISPOR 2016, Washington DC
Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases
May 2016
To investigate the prevalence and prognostic value of SF3B1 and EIF1AX mutations in uveal melanoma (UM) patients.
Publication: Ophthalmology
A cost-effectiveness analysis of a test that predicts risk of malignant progression in Barrett’s esophagus
May 2016
TissueCypher is cost-saving after five years and improves patient outcomes due to improving the effectiveness of surveillance and treatment.
Publication: Podium presentation (CN4) at ISPOR 2016, Washington DC
A tissue systems pathology test detects a field effect associated with high grade dysplasia and esophageal cancer in Barrett’s esophagus patients
May 2016
TissueCypher better predicts presence of HGD and EAC in BE than pathologic variables, and can improve on histology to identify patients requiring therapy.
Publication: Poster presentation (Sa1257) at DDW 2016, San Diego